TRION Pharma

TRION Pharma GmbH is a privately owned biopharmaceutical company that has developed a new approach to cancer immunotherapy. The company’s unique series of trifunctional therapeutic antibodies, known as Triomab®, can simultaneously activate multiple anti-cancer immune defense mechanisms. Removab® (catumaxomab), the most advanced candidate in the Triomab® family, has received EU market approval for the intraperitoneal treatment of malignant ascites.